Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial

MLA

Oliva, Stefania, et al. “Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial.” Blood, vol. 136, no. 1, Number 1 Supplement 1, Nov. 2020, pp. 44–45. EBSCOhost, https://doi.org/10.1182/blood-2020-137351.

APA

Oliva, S., Genuardi, E., Petrucci, M. T., D’Agostino, M., Auclair, D., Spadano, A., Jacob, A. P., Cea, M., De Rosa, L., Gozzetti, A., Ruggeri, M., Capra, A., Gilestro, M., Pescosta, N., Palmas, A. D., Siniscalchi, A., Kirsch, I. R., Corradini, P., Musto, P., … Gay, F. (2020). Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial. Blood, 136(1, Number 1 Supplement 1), 44–45. https://doi.org/10.1182/blood-2020-137351

Chicago

Oliva, Stefania, Elisa Genuardi, Maria Teresa Petrucci, Mattia D’Agostino, Daniel Auclair, Antonio Spadano, Allison P. Jacob, et al. 2020. “Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial.” Blood 136 (1, Number 1 Supplement 1): 44–45. doi:10.1182/blood-2020-137351.